Boston Therapeutics Enrolls Patients With Type 2 Diabetes in a Phase IIb Clinical Trial With PAZ320

MANCHESTER, NH -- (Marketwired) -- 11/12/13 -- Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovator in designing drugs that address diabetes using complex carbohydrate chemistry, today began enrolling patients in a Phase IIb clinical study on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes.

A total of 24 patients with Type 2 diabetes currently being treated with metformin will be administered PAZ320 under double-blind, placebo-controlled conditions. Patients' blood glucose will be monitored using continuous glucose monitors (CGM) and their post-prandial (after-meal) blood glucose levels will be measured following a test meal. The primary endpoint of the study is the evaluation of the effect of PAZ320 compared to placebo in the area under the curve (AUC) of glucose and on insulin levels in the blood for four hours following intake of the meal. The study is being conducted at Centre Hospitalier Robert Bisson, Lisieux, France.

David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, "This trial is designed to build upon the positive results from our Dartmouth Medical Center Phase IIa trial for PAZ320, recently published in the peer-reviewed journal, Endocrine Practice. In the Phase IIa study, PAZ320 was well tolerated in patients taking various anti-diabetic agents, including metformin. The Phase IIb trial, which focuses on patients taking only metformin, is the next step in the investigation of this compound as a potential adjunct to metformin in patients living with Type 2 diabetes. We believe it is important to better control glucose levels throughout the day, given the many complications that stem from uncontrolled diabetes."

Metformin is the most widely prescribed drug for diabetes and often the first drug prescribed to newly diagnosed diabetes patients.

**About PAZ320**

PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. PAZ320 is a proprietary polysaccharide to be
taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars, reducing the availability of glucose for absorption into the bloodstream.

**About Boston Therapeutics, Inc.**

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing drugs using complex carbohydrate chemistry. The Company’s product pipeline is focused on developing and commercializing therapeutic molecules that address Type 2 diabetes, including: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at [www.bostonti.com](http://www.bostonti.com).

**Forward Looking Statements**

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of our drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in the trials could delay obtaining meaningful results from Phase II and/or preparing for Phase III with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including PAZ320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-
looking statements.

**Contact:**

Boston Therapeutics, Inc.
Anthony Squeglia
Vice President of Strategic Planning
Phone: 603-935-9799
Email: anthony.squeglia@bostonti.com
www.bostonti.com

Source: Boston Therapeutics